Catalyst Pharmaceuticals (NASDAQ:CPRX) Upgraded by StockNews.com to Strong-Buy Rating

StockNews.com upgraded shares of Catalyst Pharmaceuticals (NASDAQ:CPRX) from a buy rating to a strong-buy rating in a research report released on Friday.

CPRX has been the topic of a number of other research reports. Stephens started coverage on shares of Catalyst Pharmaceuticals in a research note on Monday, November 18th. They issued an “overweight” rating and a $35.00 target price on the stock. Truist Financial upped their target price on shares of Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the company a “buy” rating in a research note on Monday, November 11th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $30.00 price objective on shares of Catalyst Pharmaceuticals in a research note on Friday, November 8th. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Catalyst Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $31.14.

Catalyst Pharmaceuticals Stock Down 1.0 %

NASDAQ CPRX opened at $21.31 on Friday. The stock has a market cap of $2.54 billion, a P/E ratio of 18.06, a PEG ratio of 3.35 and a beta of 0.75. The company’s 50-day simple moving average is $21.80 and its 200 day simple moving average is $19.73. Catalyst Pharmaceuticals has a twelve month low of $13.12 and a twelve month high of $24.27.

Insider Activity

In other news, insider Steve Miller sold 50,000 shares of the stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $21.93, for a total transaction of $1,096,500.00. Following the sale, the insider now directly owns 686,996 shares of the company’s stock, valued at $15,065,822.28. This represents a 6.78 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Gary Ingenito sold 12,000 shares of the stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $22.72, for a total transaction of $272,640.00. Following the sale, the insider now directly owns 51,391 shares in the company, valued at $1,167,603.52. This trade represents a 18.93 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 79,500 shares of company stock valued at $1,754,140 over the last three months. 11.00% of the stock is owned by insiders.

Hedge Funds Weigh In On Catalyst Pharmaceuticals

Large investors have recently bought and sold shares of the business. GAMMA Investing LLC lifted its holdings in Catalyst Pharmaceuticals by 62.1% in the third quarter. GAMMA Investing LLC now owns 1,778 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 681 shares during the period. nVerses Capital LLC acquired a new position in Catalyst Pharmaceuticals in the third quarter valued at approximately $50,000. Larson Financial Group LLC lifted its holdings in Catalyst Pharmaceuticals by 27,218.2% in the third quarter. Larson Financial Group LLC now owns 3,005 shares of the biopharmaceutical company’s stock valued at $60,000 after buying an additional 2,994 shares during the period. Meeder Asset Management Inc. acquired a new position in Catalyst Pharmaceuticals in the second quarter valued at approximately $70,000. Finally, Quantbot Technologies LP acquired a new position in Catalyst Pharmaceuticals in the third quarter valued at approximately $151,000. 79.22% of the stock is currently owned by institutional investors and hedge funds.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.